Evidence map›Paper›PMID 33451166›Full record

ReviewBiomolecules2021

Microglia-Mediated Neurodegeneration in Perinatal Brain Injuries.

Bobbi Fleiss, Juliette Van Steenwinckel, Cindy Bokobza, Isabelle K Shearer, Emily Ross-Munro, Pierre Gressens

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Article
  3. Beyond Histamine Blockade: Clemastine Fumarate as a Promoter of Myelin Regeneration, Inflammatory Regulation, and Neuroimmune Modulation in CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Delayed necrostatin-1s infusion attenuates cystic white matter injury in preterm fetal sheep.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Bobbi FleissSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3085, Australia.ORCID 0000-0001-7828-673X
Juliette Van SteenwinckelNeuroDiderot, Inserm, Université de Paris, 75019 Paris, France.
Cindy BokobzaNeuroDiderot, Inserm, Université de Paris, 75019 Paris, France.
Isabelle K ShearerSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3085, Australia.
Emily Ross-MunroSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3085, Australia.
Pierre GressensNeuroDiderot, Inserm, Université de Paris, 75019 Paris, France.ORCID 0000-0002-0909-4221
Inserm · FRRMIT University · AU

Funding

ERA-NET Neuron MicroMet and TRAINSHorizon H2020 PREMSTEM-874721Investissement d'Avenir ANR-11-INBS-0011-NeurATRISInvestissement d'Avenir ANR-17-EURE-001-EUR G.E.N.E
6 · The paper itself

Abstract

Perinatal brain injuries, including encephalopathy related to fetal growth restriction, encephalopathy of prematurity, neonatal encephalopathy of the term neonate, and neonatal stroke, are a major cause of neurodevelopmental disorders. They trigger cellular and molecular cascades that lead in many cases to permanent motor, cognitive, and/or behavioral deficits. Damage includes neuronal degeneration, selective loss of subclasses of interneurons, blocked maturation of oligodendrocyte progenitor cells leading to dysmyelination, axonopathy and very likely synaptopathy, leading to impaired connectivity. The nature and severity of changes vary according to the type and severity of insult and maturation stage of the brain. Microglial activation has been demonstrated almost ubiquitously in perinatal brain injuries and these responses are key cell orchestrators of brain pathology but also attempts at repair. These divergent roles are facilitated by a diverse suite of transcriptional profiles and through a complex dialogue with other brain cell types. Adding to the complexity of understanding microglia and how to modulate them to protect the brain is that these cells have their own developmental stages, enabling them to be key participants in brain building. Of note, not only do microglia help build the brain and respond to brain injury, but they are a key cell in the transduction of systemic inflammation into neuroinflammation. Systemic inflammatory exposure is a key risk factor for poor neurodevelopmental outcomes in preterm born infants. Based on these observations, microglia appear as a key cell target for neuroprotection in perinatal brain injuries. Numerous strategies have been developed experimentally to modulate microglia and attenuate brain injury based on these strong supporting data and we will summarize these.

Indexed as

AnimalsBrain InjuriesHumansInflammationInterneuronsMicrogliaNerve DegenerationNeuroprotectionencephalopathyneurodegenerative disordersneuroinflammationneuroprotectionprematuritystroke

Identifiers

PMID33451166
PMCPMC7828679
OpenAlexW3119369959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.